Monitoring Thiopurine Metabolites in Korean Pediatric Patients with Inflammatory Bowel Disease

Mi Jin Kim,1 Soo Youn Lee,2 and Yon Ho Choe3

1Department of Pediatrics, Ilsan Paik Hospital, Inje University College of Medicine, Goyang; Departments of 2Laboratory Medicine and Genetics and 3Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Received: October 28, 2013
Revised: February 13, 2014
Accepted: March 3, 2014
Corresponding author: Dr. Yon Ho Choe, Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea. Tel: 82-2-3410-3539, Fax: 82-2-3410-0043 E-mail: i101016@skku.edu

© Copyright: Yonsei University College of Medicine 2014
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose: This study aimed to assess the role of thiopurine S-methyltransferase (TPMT) and 6-thioguanine nucleotide (6-TGN) as predictors of clinical response and side effects to azathioprine (AZA), and estimate the optimal AZA dose in Korean pediatric inflammatory bowel disease (IBD) patients.

Materials and Methods: One hundred and nine pediatric IBD patients in whom AZA treatment was required were enrolled. Thiopurine metabolites were monitored since September 2010. Among them, 83 patients who had prescribed AZA for at least 3 months prior to September 2010 were enrolled and followed until October 2011 to evaluate optimal AZA dose, adverse effects and disease activity before and after thiopurine metabolite monitoring.

Results: The result of the TPMT genotype was that 102 patients were *1/*1 (wild type), four were *1/*3C, one was *1/*6, one was *1/*16 (heterozygote) and one was *3C/*3C (homozygote). Adverse effects happened in 31 patients pre-metabolite monitoring and in only nine patients post-metabolite monitoring. AZA dose was 1.4±0.31 mg/kg/day before monitoring and 1.1±0.46 mg/kg/day after monitoring (p<0.001). However, there were no statistical differences in disease activity during metabolite monitoring period (p=0.34). Adverse effects noticeably decreased although reduction of the AZA dose since monitoring.

Conclusion: TPMT genotype and thiopurine metabolite monitoring could be helpful to examine TPMT genotypes before administering AZA and to measure 6-TGN concentrations during prescribing AZA in IBD patients.

Key Words: Inflammatory bowel disease, azathioprine, thiopurine S-methyltransferase, 6-thioguanine nucleotide

INTRODUCTION

Inflammatory bowel disease (IBD), which includes Crohn’s disease (CD) and ulcerative colitis (UC), is characterized by chronic relapsing inflammation of the gastrointestinal tract. Azathioprine (AZA) is the most common drug used to maintain clinical remission in CD and UC.1,2 This drug is also important as a steroid-sparing agent in steroid-dependent and chronically active IBD. However, the dose of AZA has to be reduced or the therapy has to be discontinued in 9–28% of patients because of drug-induced toxicity.3 Bone marrow suppression, gastrointestinal...
disturbances, hepatotoxicity, pancreatitis, fever, and rash are among the most frequent reasons for AZA reduction/cessation in some patients. Although there are some adverse reactions that clinicians should be aware of, monitoring 6-thioguanine nucleotide (6-TGN) and 6-methylmercaptopurine (6-MMP) levels enables safe and long-term remission in IBD patients.\(^5\,^6\)

Thiopurine S-methyltransferase (TPMT) is the key enzyme in the metabolic pathway of thiopurine compounds. Patients with low enzyme activity have elevated 6-TGN levels and an increased risk of bone marrow suppression when treated with standard doses of AZA. Patients with high enzyme activity are either resistant to AZA due to shunting of thiopurine drugs down the 6-MMP pathway\(^9\,^10\) or require a high dose to achieve efficacy, but have an increased risk of hepatotoxicity due to high 6-MMP levels.\(^12\,^13\)

About 10% of the patients are intermediate activity group due to heterozygosity of the TPMT, and 0.3% of the patients have undetectable TPMT activity as an homozygote.\(^9\)

The wild type is TPMT*1, and TPMT*3A is the most common mutant allele (85%) in Caucasians and TPMT*3C is the most prevalent mutant allele in Africans and Asians.\(^12\,^13\)

The aim of this study was to evaluate the role of 6-TGN and TPMT as predictors of adverse effects and clinical response to AZA, using a well-powered study of pediatric patients with IBD. We also tried to determine the optimal dose of AZA maintaining remission in the Korean pediatric IBD patients.

**MATERIALS AND METHODS**

**Patients**

Among pediatric patients who were diagnosed with CD or UC in accordance with the European Society for Pediatric Gastroenterology, Hepatology and Nutrition–Porto criteria\(^15\) at the Samsung Medical Center from March 2004 to October 2011, we enrolled 109 patients who required AZA to maintain remission. There were 87 CD patients and 22 UC patients ranging in age from 3 to 21 years. Before using AZA, the TPMT genotype was analyzed. The patients had been prescribed a consistent dose of AZA for at least 3 months prior to the study. A retrospective chart analysis was conducted by physician notes, laboratory studies, radiology reports, endoscopy records, and histology reports. This study was approved by our Institutional Review Board.

Analysis of TPMT genotype was available throughout the study period, and thiopurine metabolite monitoring has been available since September 2010. One hundred and nine IBD patients have been monitored for thiopurine metabolites since September 2010. Of them, 83 cohorts who had received a consistent dose of AZA for at least 3 months prior to September 2010 were selected and followed until October 2011 for the assessment of adverse drug reactions (ADR), disease activity and optimal AZA dose to maintain remission at pre- and post-thiopurine metabolite monitoring period. The appraisal of ADR, disease activity and AZA dose in 83 patients was performed and compared between just before the beginning of thiopurine metabolite monitoring (September 2010) and when 6-TGN level attained an optimal therapeutic range of approximately 235–450 pmol/8×10^9 red blood cells (RBC).\(^16\,^17\)

AZA treatment was initiated at a dose of approximately 1.0 mg/kg per day and then increased to approximately 1.5 mg/kg per day in order to maintain remission during maintenance therapy. Patients were required to visit the outpatient clinic at least once a month before remission of the disease, and once every 2 to 3 months after remission was obtained. Laboratory tests were conducted in order to monitor disease activity and adverse drug reactions at each visit. Routine blood examinations including complete blood cell counts, erythrocyte sedimentation rate, albumin, transaminase, amylase, lipase and C-reactive protein were carried out. Disease activity was evaluated using the pediatric UC activity index (PUCAI)\(^18\) and the pediatric CD activity index (PCDAI).\(^19\) In both activity indices, scores of less than 10 points are considered to be in remission, while scores above 10 points are considered indicative of active disease.

**Analysis of the TPMT genotype**

Whole blood specimens were collected into EDTA tubes, and genomic DNA was isolated from peripheral blood leukocytes using the Wizard Genomic DNA Purification kit according to the manufacturer’s instructions (Promega, Madison, WI, USA).

All nine exons of the TPMT gene were amplified on a model 9700 thermal cycler (Applied Biosystems, Foster City, CA, USA) using oligonucleotide primers and conditions as previously described with some modifications.\(^20\,^21\)

Direct sequencing was performed using ABI Big Dye Terminator kit v1.1 (Applied Biosystems) according to the manufacturer’s instructions. To identify sequence variations, patient sequences were compared with respective reference sequences using the Sequencher software (Gene Codes Corporation, Ann Arbor, MI, USA).
6-TGN and 6-MMP assay
Measurements of the RBC 6-TGN and 6-MMP levels were performed on the Waters 2795 Alliance high-performance liquid chromatography system and a Quatro Micro API tandem mass spectrometer (Waters, Manchester, UK). Six calibrators and two control materials (mixture with 6-TGN and 6-MMP stock solutions and RBCs from pooled whole blood after removal of plasma and buffy coat) were used in each analysis. Within-run and between-run imprecision for thiopurine metabolites were below 10%. The limit of quantification was 5 ng/mL for 6-TGN and 50 ng/mL for 6-MMP.

Statistical methods
All collected variables were subjected to descriptive analysis. Results are expressed as mean±standard deviation or range for numerical variables and as percentages for qualitative variables. A Student t-test or Mann-Whitney U test was used to compare numerical variables between groups and the χ² test or Fisher exact test was used to investigate the relationship between the variables. A p-value <0.05 was considered statistically significant.

RESULTS

Baseline patient characteristics
A total of 109 patients were studied. All patients were treated with AZA; the mean dose of AZA was 1.2±0.38 mg/kg/day. The demographic and clinical characteristics of patients enrolled in this study are shown in Table 1.

The mean 6-TGN concentration of the entire study population was 328.3±105.0 pmol/8×10⁸ RBC. The mean 6-TGN concentration was 299.7±77.1 pmol/8×10⁸ RBC in patients with active disease (n=24), and 336.3±110.7 pmol/8×10⁸ RBC among patients in remission (n=85). There were no statistical differences in 6-TGN levels between patients with active disease and patients in remission (p=0.73).

Frequency of ADR during AZA treatment
Definitions of ADR in this study are shown in Table 2. ADR occurred in 38 patients (34.8%). Among these patients, gastrointestinal intolerance occurred in two patients (1.8%), rash in two (1.8%), leukopenia in 24 (22.0%) and hair loss in 10 (9.2%) (Table 2). Only three of 24 leukopenia events could be explained by TPMT mutation. The mean AZA dose was 1.1±0.53 mg/kg/day in patients developing ADR, which was not significantly different from that (1.2±0.35 mg/kg/day) of the patients who did not develop ADR (p=0.45).

Patient characteristics with TPMT mutation
The distribution of the TPMT genotype was as follows: 102 patients had *1/*1 (wild type), one had *3C/*3C (homozygote, NM_000367.2: c.719A>G; p.Tyr240Cys), four had *1/*3C, one had *1/*6, and one had *1/*16 (heterozygote). There were no statistical differences in initial AZA dose between the group of wild type TPMT and TPMT mutation. However, the 6-TGN concentration was 416.8±271.7 pmol/8×10⁸ RBC in patients with wild type TPMT and 1822.9±1493.9 pmol/8×10⁸ RBC in TPMT mutation (p=0.001). There were also statistical differences in white blood cell counts among two groups (p=0.028) (Table 3). The patient with *3C/*3C mutation required low dose of AZA, 0.18 mg/

Table 1. Baseline Clinical Characteristics

|                  | CD (n=87) | UC (n=22) | Total (n=109) |
|------------------|-----------|-----------|---------------|
| Sex (male/female)| 62/25     | 13/9      | 75/34         |
| Age (yrs; mean+range) | 15.9 (3-21) | 15.5 (10-20) | 15.8 (3-21) |
| Number of mesalamine treatments | 73        | 20        | 93            |
| Location of CD   |           |           |               |
| Ileal            | 8         |           |               |
| Ileocolonic      | 57        |           |               |
| Colonic          | 22        |           |               |
| Active (PCDAI≥10)| 20        |           |               |
| In remission (PCDAI<10) | 67        |           |               |
| Type of UC       |           |           |               |
| Distal colitis   | 9         |           |               |
| Extensive colitis| 13        |           |               |
| Active (PUCAI≥10)| 4         |           |               |
| In remission (PUDAI<10) | 18        |           |               |
| AZA dose (mean±SD, mg/kg/day) | 1.2±0.39 | 1.2±0.50 | 1.2±0.38 |

AZA, azathioprine; CD, Crohn’s disease; UC, ulcerative colitis; PCDAI, pediatric CD activity index; PUDAI, pediatric UC activity index.
AZA, azathioprine; TPMT, thiopurine S-methyltransferase.

Table 2. Definitions and Frequencies of Adverse Drug Reactions (ADR) Encountered in the Study

| ADR               | Definition of ADR                                                                                                                                                                                                 | Number | % of ADRs in overall patients | Number of TPMT polymorphism with ADRs |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|------------------------------|--------------------------------------|
| Gastric intolerance | Occurrence of any or a combination of nausea, vomiting and abdominal pain with normal amylase and abdominal ultrasound                                                                                       | 2      | 1.8                          | 0                                    |
| Rash              | New onset of rash after starting AZA which resolves on withdrawal of AZA                                                                                                                                       | 2      | 1.8                          | 2                                    |
| Leukopenia        | Total white blood cell count <3500/mm³                                                                                                                                                                          | 24     | 22.0                        | 3                                    |
| Hair loss         | New onset of hair loss after starting AZA which resolves on withdrawal of AZA                                                                                                                                    | 10     | 9.2                          | 3                                    |
| Total             |                                                                                                                                                                                                                | 38     | 34.8                        | 8                                    |

AZA, azathioprine; TPMT, thiopurine S-methyltransferase.

Table 3. Comparison of AZA Dose, 6-TGN Concentration and White Blood Cell Counts between the Group of Wild Type TPMT and TPMT Mutation

|                          | Wild type TPMT (n=102) | TPMT mutation (n=7) | p value |
|--------------------------|------------------------|---------------------|---------|
| AZA dose                 | 1.2±0.39               | 1.2±0.32            | >0.05   |
| 6-TGN concentration      | 416.8±271.1            | 1822.9±1493.9       | 0.001   |
| WBC counts               | 9821.3±6722.4          | 6875.7±4842.5       | 0.028   |

AZA, azathioprine; WBC, white blood cell; 6-TGN, 6-thioguanine nucleotide; TPMT, thiopurine S-methyltransferase.

Table 4. Characteristics of Inflammatory Bowel Disease Patients with TPMT Mutation

| Patient no. | Age (yrs)/sex | Disease | TPMT mutation | Initial Dosage of AZA (mg/kg/day) | Initial 6-TGN (pmol/8×10⁸ RBC) | Initial WBC (/mm³) | Follow-up Dosage of AZA (mg/kg/day) | Follow-up 6-TGN (pmol/8×10⁸ RBC) | Follow-up WBC (/mm³) | ADR                        |
|-------------|---------------|---------|---------------|----------------------------------|-------------------------------|-------------------|-------------------------------------|----------------------------------|-----------------------|---------------------------|
| 1           | 21/M          | CD      | *3C/*3C       | 0.76                             | 7205.8                        | 2550              | 0.18                                | 436.6                            | 4930                  | Leukopenia                |
| 2           | 21/F          | CD      | *1/*3C        | 1.27                             | 538.0                         | 7990              | 0.42                                | 240.8                            | 7410                  | -                         |
| 3           | 18/M          | CD      | *1/*3C        | 0.88                             | 446.2                         | 3100              | 0.85                                | 373.1                            | 2820                  | Hair loss, rash, leukopenia |
| 4           | 15/M          | CD      | *1/*3C        | 1.39                             | 609.8                         | 16220             | 0.19                                | 468.6                            | 8780                  | Hair loss                 |
| 5           | 19/F          | CD      | *1/*3C        | 1.56                             | 2621.8                        | 2830              | 0.26                                | 310.0                            | 4720                  | Hair loss, rash, leukopenia |
| 6           | 18/M          | CD      | *1/*6         | 1.44                             | 774.1                         | 6890              | 0.92                                | 318.4                            | 7450                  | -                         |
| 7           | 15/M          | UC      | *1/*16        | 0.85                             | 564.3                         | 8550              | 0.42                                | 370.1                            | 5060                  | -                         |

AZA, azathioprine; CD, Crohn’s disease; UC, ulcerative colitis; WBC, white blood cell; 6-TGN, 6-thioguanine nucleotide; TPMT, thiopurine S-methyltransferase; ADR, adverse drug reactions; RBC, red blood cells.

Comparison of ADR, disease activity and AZA dose at pre- and post-thiopurine metabolite monitoring

Sixty-seven CD patients and 16 UC patients were selected for assessing ADR, disease activity (PCDAI or PUCAI) and AZA dose before and after thiopurine metabolite monitoring. ADR happened in 31 patients pre-metabolite monitoring and in only nine patients post-metabolite monitoring. AZA dose was 1.4±0.31 mg/kg/day before monitoring and 1.1±0.46 mg/kg/day after monitoring (p<0.001). However, there were no statistical differences in disease activity during metabolite monitoring period (p=0.34) (Table 5).

DISCUSSION

Thiopurine has been commonly used for the maintenance of remission or for treating chronic active lesions in IBD.
The use of AZA in adult patients with IBD has been well documented in the literature and also recently reported in pediatric studies. Present, et al. demonstrated that 67% of adult patients significantly decreased or terminated their steroid therapy 3–6 months after the introduction of oral immunomodulators. Similar results have been demonstrated in pediatric patients.

One of the potentially severe side effects in AZA therapy is myelosuppression. AZA-induced bone marrow suppression has been attributed to the low enzyme activity caused by TPMT genetic polymorphism. Genetic polymorphism results in greater conversion of AZA to 6-TGN likely due to myelotoxicity. Consequently, the monitoring of 6-TGN levels has been known to be useful for managing IBD patients treating with AZA, since it may confirm the optimal AZA dose to maximize efficacy while minimizing the risk of side effect. The aim of this study was to investigate the influence of TPMT genotype and 6-TGN concentrations on the development of adverse effects during AZA treatment in children and adolescents with IBD.

TPMT can be examined for based on phenotype or genotype tests. TPMT genotyping is the method for detecting single nucleotide polymorphism responsible for TPMT inactivation. There is a good correlation between TPMT activity and genotyping. The population can be divided into three groups founded on TPMT genetic polymorphism: wild type TPMT with high methylation activity (88%), heterozygosity with intermediate activity (11%) and homozygosity for deficient TPMT alleles with a low activity (0.3%). Until now, 27 TPMT alleles which are *2, *3A, *3B, *3C, *3D, and *4 to *25 responsible for possible deficient activity have been detected.

In Asian populations, including Koreans, the frequencies of TPMT mutation are lower than those reported for Western countries. While the heterozygous *2 or *3A mutations are rare, *3C mutation is most frequent and myelotoxicity develops more frequently in East Asia. The reason why Asian patients are troubled with bone marrow suppression during AZA administration is still unclear. One possible theory is the difference in TPMT genetic polymorphisms between Asian and Caucasian populations.

A TPMT genotyping study of 400 Korean subjects suggested that TPMT *1/*1 (wild type) was 97.8% (391/400). TPMT *1/*3C was found to be the most frequent polymorphism in the Korean population (1.8%). TPMT *2, *3A, and *3B were not found in the study population. Two Korean subjects were genotyped as TPMT *1/*6 (0.5%). Another TPMT study of 147 Japanese IBD patients suggested that wild type for TPMT was 98.0% (144/147) and TPMT *1/*3C was 2.0% (3/147) similar to Korean study. To our knowledge, our study is the first work to detect TPMT *3C/*3C and *1/*16 mutations and to evaluate 6-TGN concentrations and dosing of optimal AZA in Korean pediatric IBD patients. In our study, TPMT polymorphism was proven in seven patients. The patients with TPMT polymorphism required a low dose of AZA to attain an optimal therapeutic range of 6-TGN. TPMT *3C/*3C and *1/*3C mutation was highly associated with a risk of ADR as it is known. However, TPMT *1/*6 and *1/*16 mutations were not related with ADR. There is no doubt that TPMT testing is necessary before initiation of AZA to identify individuals who are homozygote recessive or have extremely low TPMT activity. However, TPMT testing doesn’t predict all cases of ADR such as leukopenia. Mutations of TPMT have been associated with leukopenia, although other studies have reported that leukopenia is independent of TPMT polymorphisms.

| Table 5. Comparison of ADR, Disease Activity and AZA Dose at Pre- and Post-Thiopurine Metabolite Monitoring in 83 IBD Patients |
|-----------------|-----------------|-----------------|
|                 | Pre-monitoring  | Post-monitoring |
| ADR             | 31              | 9               |
| Rash            | 2               | 0               |
| Leukopenia      | 24              | 9               |
| Hair loss       | 5               | 0               |
| Disease activity| 5.6±4.3         | 4.5±3.9         |
| AZA dose        | 1.4±0.31        | 1.1±0.46        | <0.001 |

ADR, adverse drug reactions; AZA, azathioprine; IBD, inflammatory bowel disease.
and a therapeutic range of 6-TGN concentration is 235–450 pmol/8×10⁸ RBC. A 6-TGN concentration of >235 pmol/8×10⁸ RBC is associated with clinical response. The cutoff concentration above 450 pmol/8×10⁸ RBC is based on an increased risk of side effects (myelotoxicity and nodular regenerative hyperplasia of the liver) without an increase in efficacy. Patients with erythrocyte 6-MMP concentrations above 5700 pmol/8×10⁸ RBC are at increased risk of hepatotoxicity and are unlikely to respond to treatment by increasing the drug dose. These patients are possibly preferentially metabolizing AZA through TPMT to form 6-MMP and may profit from reducing thiopurine dose by 50–75%, as well as careful monitoring of hematological parameters.

Osterman, et al. and Sandborn, et al. documented that the doses of AZA in maintenance therapy to treat IBD were 2–3 mg/kg/day, and that 6-TGN concentrations above 235 pmol/8×10⁸ RBC were confirmed in most IBD patients with this dose. A study of Japanese children with IBD showed that similar 6-TGN concentrations should be targeted to maintain remission, although the amounts of AZA required to achieve the targeted 6-TGN concentration were lower than those used in Western countries. In Korea, lower doses of AZA (approximately 1.5–2 mg/kg AZA per day) are empirically used for the treatment of IBD patients. However, there has been no data on the dose of AZA that is needed to reach appropriate 6-TGN level in Korean children and adolescents with IBD.

In agreement with previous investigations, our study showed that the mean 6-TGN concentration was higher in patients with clinical remission (336.3±110.7 pmol/8×10⁸ RBC) than with active disease (299.7±77.1 pmol/8×10⁸ RBC). However, there were no statistical differences. In the present study, since thiopurine metabolite monitoring, ADR has markedly decreased and AZA dose reduced to 1.1±0.46 mg/kg/day with maintaining remission. Only 8 of 38 ADR events were associated with TPMT polymorphism; and the rest of the ADR events occurred in wild type of TPMT. Therefore, surveillance of ADR through thiopurine metabolite monitoring is possibly important to the patients, with not only TPMT polymorphism but also wild type of TPMT.

As we described above, our results indicated that 6-TGN concentration was higher than we expected in pediatric IBD patients, even though they were treated with low-dose of AZA. These results are similar to those of a study conducted in the Far East, however, different from studies reported in Western countries. One explanation for this might be an ethnic difference.

Our study had several limitations, including the small number of patients and the retrospective design. In Korea, the incidence and prevalence of IBD are still low compared with those in Western countries. Considering these circumstances, we recruited not a few number of pediatric patients with IBD in Korea. Monitoring 6-TGN concentrations is helpful in developing a therapeutic strategy for pediatric and adolescent IBD patients. Although TPMT genotype and thiopurine metabolite monitoring could not completely explain the thiopurine-induced ADR, it could be helpful to examine TPMT genotypes before administering AZA and to measure 6-TGN concentrations during prescribing AZA in IBD patients. Clinicians should be cautious about the possibility of higher 6-TGN concentrations in Korean pediatric IBD patients, even if they are being treated with general AZA dose.

ACKNOWLEDGEMENTS

This study was supported by the Samsung Biomedical Research Institute grant, no. SBRI C-A6-229-3.

REFERENCES

1. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn’s disease. Cochrane Database Syst Rev 2000: CD000545.
2. Hibi T, Ogata H. Novel pathophysiological concepts of inflammatory bowel disease. J Gastroenterol 2006;41:10-6.
3. Hindorf U, Lindqvist M, Peterson C, Söderkvist P, Ström M, Hjortswang H, et al. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut 2006;55:1423-31.
4. Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol Drug Saf 2004;13:563-7.
5. Goldenberg BA, Rawsthorne P, Bernstein CN. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease. Am J Gastroenterol 2004;99:1744-8.
6. Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001;48:642-6.
7. Lennard L, Van Loon JA, Lileyman JS, Weinshilboum RM. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther 1987;41:18-25.
8. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyl-
transferase genetic polymorphism. Clin Pharmacol Ther 1989;46: 149-54.
9. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, et al. Molecular diagnosis of thiopurine S-methyltransferase
deficiency: genetic basis for azathioprine and mercaptopurine in
tolerance. Ann Intern Med 1997;126:608-14.
10. Cuffari C, Dassopoulos T, Turnbull L, Thompson RE, Bayless TM. Thiopurine methyltransferase activity influences clinical re
sponse to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol 2004;2:410-7.
11. Lennard L, Lilleleyman JS, Van Loon J, Weinsbouam RM. Genet
ic variation in response to 6-mercaptopurine for childhood acute
lymphoblastic leukemia. Lancet 1990;336:225-9.
12. Winter JW, Gaffney D, Shapiro D, Spooner RJ, Marinaki AM, Sanderson JD, et al. Assessment of thiopurine methyltransferase enzy
me activity is superior to genotype in predicting myelosuppres
sion following azathioprine therapy in patients with inflam
matory bowel disease. Aliment Pharmacol Ther 2007;25:1069-77.
13. Ishioka S, Hykama K, Sato H, Yamanishi Y, McLeod HL, Kum
agai K, et al. Thiopurine methyltransferase genotype and the toxi
city of azathioprine in Japanese. Intern Med 1999;38:944-7.
14. Cao Q, Zhu Q, Shang Y, Gao M, Si J. Thiopurine methyltrans
ferase gene polymorphisms in Chinese patients with inflammatory
bowel disease. Digestion 2009;79:58-63.
15. IBD Working Group of the European Society for Paediatric Gas
troenterology, Hepatology and Nutrition. Inflammatory bowel dis
cease in children and adolescents: recommendations for diagnosis--
the Porto criteria. J Pediatr Gastroenterol Nutr 2005;41:1-7.
16. Derijks LJ, Gilissen LP, Hooymans PM, Hommes DW. Review article: thiopurines in inflammatory bowel disease. Aliment Phar
macol Ther 2006;24:715-29.
17. Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine phar
macogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol 2005;20:1149-57.
18. Turner D, Otle AR, Mack D, Hyams J, de Bruine J, Usoue K, et al. Development, validation, and evaluation of a pediatric ulcer
colitis activity index: a prospective multicenter study. Gastroenterology 2007;133:423-32.
19. Hyams J, Markowitz J, Otle A, Rosh J, Mack D, Bousvaros A, et al. Evaluation of the pediatric crotch disease activity index: a pro
pective multicenter experience. J Pediatr Gastroenterol Nutr 2005;41:416-21.
20. Dorababu P, Nagesh N, Linga VG, Gundeti S, Kutala VK, Red
danna P, et al. Epistatic interactions between thiopurine methyl
transferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) variations determine 6-mercaptopurine toxicity in Indian
children with acute lymphoblastic leukemia. Eur J Clin Pharmacol 2012;68:379-87.
21. Zabala-Fernández W, Barreiro-de Acosta M, Echarri A, Carpio D, Lorenzano A, Castro J, et al. A pharmacogenetics study of TPMT
and ITPA genes detects a relationship with side effects and clinical re
sponse in patients with inflammatory bowel disease receiving Azathiprine. J Gastrointestin Liver Dis 2011;20:247-53.
22. Derieux T, Meyer G, Barham R, Matsutani M, Barry M, Bouliu
R, et al. Liquid chromatography-tandem mass spectrometry analy
sis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients re
ceiving azathioprine/6-mercaptopurine therapy. Clin Chem 2005;51:2074-84.
23. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Paster
nack BS. Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980;
302:981-7.
24. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel dis
ease: short- and long-term toxicity. Ann Intern Med 1989;111:641-9.
25. Hanauer SB, Baert F. Medical therapy of inflammatory bowel dis
ease. Med Clin North Am 1994;78:1413-26.
26. Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pe
diatric patients with inflammatory bowel disease. Gastroenterolo
ry 1998;115:813-21.
27. Markowitz J, Grancher K, Mandel F, Daum F. Immunosuppress
ive therapy in pediatric inflammatory bowel disease: results of a
survey of the North American Society for Pediatric Gastroenterol
ogy and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum. Am J Gastroen
terol 1993;88:44-8.
28. Kader HA, Mascarenhas MR, Piccoli DA, Stouffer NO, Baldassa
no RN. Experiences with 6-mercaptopurine and azathioprine ther
apy in pediatric patients with severe ulcerative colitis. J Pediatr Gastroenterol Nutr 1999;28:54-8.
29. Derijks LJ, Gilissen LP, Engels LG, Bos LP, Bus PJ, Lohman JJ, et al. Pharmacokinetics of 6-thioguanine in patients with inflam
matory bowel disease. Ther Drug Monit 2006;28:45-50.
30. Haglund S, Taipalensuu J, Peterson C, Almner S. IMPDH activity in thiopurine-treated patients with inflammatory bowel disease-
relation to TPMT activity and metabolite concentrations. Br J Clin Pharmacol 2008;65:69-77.
31. Gilissen LP, Derijks LJ, Bos LP, Bus PJ, Hooymans PM, Engels LG. Therapeutic drug monitoring in patients with inflammatory
bowl disease and established azathioprine therapy. Clin Drug In
vestig 2004;24:479-86.
32. Schaeffeler E, Fischer C, Brockmeier D, Wernet D, Moerike K, Eichelbaum M, et al. Comprehensive analysis of thiopurine S-
methyltransferase phenotype-genotype correlation in a large popula
tion of German-Caucasians and identification of novel TPMT var
iants. Pharmacogenetics 2004;14:407-17.
33. Weinsbouam RM, Sladek SL. Mercaptopurine pharmacogenet
ics: monogenic inheritance of erythrocyte thiopurine methyltrans
ferase activity. Am J Hum Genet 1980;32:651-62.
34. Derijks LJ, Wong DR. Pharmacogenetics of thiopurines in inflam
matory bowel disease. Curr Pharm Des 2010;16:145-54.
35. Lee SS, Kim YW, Jang YJ, Shin JG. Duplex pyrosequencing of the TPMT*3C and TPMT*6 alleles in Korean and Vietnamese
populations. Clin Chim Acta 2008;398:82-5.
36. Hiratsuka M, Inoue T, Omori F, Agatsuma Y, Mizugaki M. Genet
ic analysis of thiopurine methyltransferase polymorphism in a Japa
nese population. Mutat Res 2000;448:91-5.
37. Chang JG, Lee LS, Chen CM, Shih MC, Wu MC, Tsai FJ, et al. Mo
cular analysis of thiopurine S-methyltransferase alleles in South-east Asian populations. Pharmacogenetics 2002;12:191-5.
38. Khum SK, Liu TC, Chan YH, Ariffin H, Tan PL, et al. Thiopurine S-methyltransferase activity in three major Asian popula
tions: a population-based study in Singapore. Eur J Clin Pharmaco
l 2008;64:373-9.
39. Khum SK, Tan PL, Tay AH, Heng CK, Yooz AE, Quah TC. Thiopur
ine methyltransferase polymorphisms in a multiracial asian popula
tion and children with acute lymphoblastic leukemia. J Pe
diatr Hematol Oncol 2002;24:353-9.
40. Takatsu N, Matsui T, Murakami Y, Ishihara H, Hisabe T, Nagaha

Monitoring Thiopurine Metabolite
ma T, et al. Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol 2009; 24:1258-64.
41. Collie-Duguid ES, Pritchard SC, Powrie RH, Sludden J, Collier DA, Li T, et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999;9:37-42.
42. Kumagai K, Hiyma K, Ishioka S, Sato H, Yamanishi Y, McLeod HL, et al. Allele frequency of the thiopurine methyltransferase (TPMT) gene in Japanese. Pharmacogenetics 2001;11:275-8.
43. Jun JB, Cho DY, Kang C, Bae SC. Thiopurine S-methyltransferase polymorphisms and the relationship between the mutant alleles and the adverse effects of systemic lupus erythematosus patients taking azathioprine. Clin Exp Rheumatol 2005;23:873-6.
44. Ottemess D, Szumianski C, Lennard L, Klemetsdal B, Aarbakke J, Park-Hah JO, et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 1997;62:60-73.
45. Kim JH, Cheon JH, Hong SS, Eun CS, Byeon JS, Hong SY, et al. Influences of thiopurine methyltransferase genotype and activity on thiopurine-induced leukopenia in Korean patients with inflammatory bowel disease: a retrospective cohort study. J Clin Gastroenterol 2010;44:e242-8.
46. Benkov K, Lu Y, Patel A, Rahhal R, Russell G, Teitelbaum J, et al. Role of thiopurine metabolism testing and thiopurine methyltransferase determination in pediatric IBD. J Pediatr Gastroenterol Nutr 2013;56:333-40.
47. Hibi T, Naganuma M, Kitahora T, Kinuyo F, Shimoyama T. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J Gastroenterol 2003;38:740-6.
48. Gisbert JP, Niño P, Rodrigo L, Cara C, Guijarro LG. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. Am J Gastroenterol 2006;101:2769-76.
49. Zelinkova Z, Derijks LJ, Stokkers PC, Vogels EW, van Kampen T, et al. Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Clin Gastroenterol Hepatol 2006;4:44-9.
50. Colombel JF, Ferrari N, Debveysere H, Marteau P, Gendre JP, Bonaz B, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000;118:1025-30.
51. Schwab M, Schäffeler E, Marx C, Fischer C, Lang T, Behrens C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenomics 2002;12:429-36.
52. Palmieri O, Lattano A, Bossa F, Vecchi M, D'Inca R, Guagnozzi D, et al. Sequential evaluation of thiopurine methyltransferase, inosine triphosphate pyrophosphatase, and HPRT1 genes polymorphisms to explain thiopurines’ toxicity and efficacy. Aliment Pharmacol Ther 2007;26:737-45.
53. Dubinsky MC, Lamotho S, Yang HY, Targan SR, Sinnett D, Théoret Y, et al. Pharmacogenomics and metabolic measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705-13.
54. Ooi CY, Bohnke TD, Lee D, Naidoo D, Day AS. Thiopurine metabolite monitoring in paediatric inflammatory bowel disease. Aliment Pharmacol Ther 2007;25:941-7.
55. Wright S, Sanders DS, Lobo AJ, Lennard L. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut 2004;53:1123-8.
56. Dubinsky MC. Optimizing immunomodulator therapy for inflammatory bowel disease. Curr Gastroenterol Rep 2003;5:506-11.
57. Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002;122:904-15.
58. Derijks LJ, Gilissen LP, Engels LG, Bos LP, Bus PJ, Lohman JJ, et al. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther Drug Monit 2004;26:311-8.
59. Haines ML, Ailouni Y, Irving PM, Sparrow MP, Rose R, Geary RB, et al. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease. Inflamm Bowel Dis 2011;17:1301-7.
60. Osterman MT, Kondu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006;130:1047-53.
61. Sandborn WJ. Rational dosing of azathioprine and 6-mercaptopurine. Gut 2001;48:591-2.
62. Ohtsuka Y, Arai K, Aoyagi Y, Fujii T, Yamakawa Y, Ohtani K, et al. Monitoring 6-thioguanine nucleotide concentrations in Japanese children and adolescents with inflammatory bowel disease. J Gastroenterol Hepatol 2010;25:1626-30.
63. Komiyama T, Yajima T, Kubota R, Iwao Y, Sakuraba A, Funakoshi S, et al. Lower doses of 6-mercaptopurine/azathioprine bring enough clinical efficacy and therapeutic concentration of erythrocyte 6-mercaptopurine metabolite in Japanese IBD patients. J Crohns Colitis 2008;2:315-21.
64. Lee HJ, Yang SK, Kim KJ, Choe JW, Yoon SM, Ye BD, et al. The safety and efficacy of azathioprine and 6-mercaptopurine in the treatment of Korean patients with Crohn’s disease. Intest Res 2009;7:22-31.
65. Kim JH, Cheon JH, Kim TI, Kim WH. A Survey of Actual Clinical Practice Patterns in the Treatment of Inflammatory Bowel Disease in Korea. J Gastroenterol Hepatol 2010;25:79-85.
66. Andoh A, Tsujikawa T, Ban H, Hashimoto T, Bamha S, Ogawa A, et al. Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol 2008;23:1373-7.
67. Yang SK, Yun S, Kim JH, Park JY, Kim HY, Kim YH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study. Inflamm Bowel Dis 2008;14:542-9.